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Abstract
Background: The introduction of biological agents, such as infliximab, which act against tumor necrosis factor-α
was a major advance for the treatment of an increasing number of chronic diseases. Tumor necrosis factor-α
antagonists represent a major therapeutic advance for the management of chronic inflammatory diseases, such as
psoriasis. Previous studies have reported that the use of tumor necrosis factor-α antagonists increased the risk of
opportunistic infections and reactivation of latent bacterial infections. Cardiac involvement, such as infective
endocarditis, is very rare in the literature.
Case presentation: A 77-year-old Asian man with a 10-year history of psoriatic erythroderma was referred due to
high fever and general malaise. He was treated with Predonine (prednisolone) and infliximab. After treatment,
cardiac echography showed mitral valve vegetation and brain magnetic resonance imaging indicated multiple fresh
infarctions. He died from large brain infarction in October 2013. An autopsy showed fresh thrombosis in his left
middle cerebral artery, mitral valve vegetations, and septic micro-embolisms in multiple organs.
Conclusions: Lethal bacterial endocarditis was revealed after administration of tumor necrosis factor-α inhibitor,
infliximab, for the treatment of psoriatic erythroderma. An autopsy showed vegetation in his mitral valve and brain
infarction with fresh purulent embolism in his left middle cerebral artery and septic micro-embolisms.
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Background
The introduction of biological agents, such as infliximab,
which act against tumor necrosis factor-α (TNF-α) was a
major advance for the treatment of an increasing number
of chronic diseases. TNF-α antagonists represent a major
therapeutic advance for the management of chronic in-
flammatory diseases, such as rheumatoid arthritis and
psoriasis [1]. Due to their inhibition of proinflammatory
cytokines, their use has been associated with an increased
risk of severe infection [2]. Previous studies have reported
an increased risk of opportunistic infections and
reactivation of latent bacterial infections [3]. Although
some studies concluded an increased risk of infection in
patients receiving infliximab [4], the relative risk for pa-
tients receiving TNF-α inhibitors was reported to be up to
twice that of control [5], and even higher at the treat-
ment’s onset. Cardiac involvement, such as infective endo-
carditis, is very rare in the literature [6, 7].
We report the case of a man with infective endocardi-
tis due to the TNF-α inhibitor, infliximab, for the man-
agement of psoriatic erythroderma.
Case presentation
We describe the case of a 77-year-old Asian man with a
10-year history of moderate-to-severe psoriatic erythro-
derma (Fig. 1). He was treated with an anti-histamine
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drug and steroid ointment on his psoriasis for a few
years but he was not treated with oral steroid agents.
His psoriasis worsened. Considering the clinical severity
of the features of his skin, he was treated with 14 days of
Predonine (prednisolone) 15 mg orally and one treat-
ment of infliximab 300 mg by intravenously administra-
tion in August 2013. He was discharged at the end of
August 2013 because his skin condition was better and
his itching symptom was relieved.
Three days later, he presented with shortness of
breathing, general malaise, and anorexia. He was re-
ferred to our department of cardiovascular medicine in
September 2013. His past medical history showed that
he had herpes zoster 6 months earlier. His social history
was not significant for alcoholic drinks or tobacco smok-
ing. He denied illicit drug use. His job was a farmer. No
particular environment was evident.
On physical examination, he was awake and oriented
to time, place, and self. A neurological examination
showed no abnormal reflex and no paralysis. His vital
signs revealed heart rate of 111/minute, blood pressure
of 101/49 mmHg, respiratory rate of 24/minute with an
oxygen saturation of 97 % on 3 L/minute nasal oxygen
supply. The other physical findings revealed no murmur
and no wheezing in his chest and no tenderness in his
abdomen. He underwent a series of laboratory tests. His
white blood cell (WBC) count was 29,900/mm3 and
polymorphonuclear neutrophilic cells were 84 %. His
levels of liver and renal function were within normal
range. Chest X-rays showed slight cardiac enlargement.
An electrocardiogram showed preventricular atrial con-
traction. Chest computed tomography revealed pleural
effusion and cardiac enlargement. The first cardiac echo-
graphy showed mitral valve vegetation with diffuse hypo-
kinesis of left ventricular wall motion and brain magnetic
resonance imaging (MRI) indicated multiple fresh infarc-
tions. He was given empiric therapy with piperacillin-
tazobactam administered intravenously 4.5 g twice a day.
His blood culture revealed methicillin-sensitive Staphylo-
coccus aureus infection. His antimicrobial therapy was
modified to monotherapy with daptomycin administered
intravenously 300 mg/day. Although the regimen was held
[8], his systemic conditions worsened and he was uncon-
scious. Disseminated intravascular coagulation and cardio-
genic shock progressed. The following cardiac echography
showed no mitral valve vegetation with grade III mitral re-
gurgitation. We speculated vegetation removal from his
mitral valve. He died 31 days after readmission from large
brain infarction (Fig. 2) in October 2013. An autopsy
showed fresh purulent embolism in his left middle cere-
bral artery (Fig. 3), mitral valve vegetations (Fig. 4), and
septic micro-embolisms in multiple organs.
Discussion
We described a patient with lethal bacterial endocarditis
after administration of TNF-α inhibitor, infliximab, for
the treatment of psoriatic erythroderma. An autopsy
showed vegetation in his mitral valve and brain
Fig. 1 The dorsal surface of trunk showed red-violet erythema and
fine scaling with the healed herpes zoster
Fig. 2 Computed tomography showed the large cerebral infarction
on day 29 after admission
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infarction with fresh purulent embolism in his left
middle cerebral artery and septic micro-embolisms.
Erythrodermic psoriasis is a severe variant of psoriasis
with a reported prevalence among patients with psoriasis
ranging from 1.5 to 31 % [9]. Left untreated, it may lead
to serious morbidity and even mortality. Erythrodermic
psoriasis is often difficult to manage, and the therapies
that are currently available may prove to be unsatisfac-
tory. Biological agents offer a new alternative therapeutic
approach [9], although there are no controlled trials to
support their use, particularly as a long-term therapy op-
tion. The relation between erythrodermic psoriasis and
cardiac disease is only mentioned in coronary artery dis-
ease. In many ways, psoriasis can be considered a model
autoimmune disease [10]. The most common causes of
death in patients with erythroderma are pneumonia,
septicemia, and heart failure. Older patients who develop
complications such as infection, fluid/electrolyte imbal-
ances, and cardiac failure are at higher risk of mortality
[11]. In our case, septic organ failure due to treatment-
induced bacterial endocarditis was the cause of death.
Bacteremia due to receiving TNF-α inhibitors was re-
ported [3]. The national registries suggest a small but
significantly increased incidence of serious infection ran-
ging from 1.2 to 2.78 times that of controls treated with
methotrexate [3]. Mycobacteria, Staphylococcus aureus,
Listeria monocytogenes, varicella zoster virus, and Leish-
mania species repeatedly appear in the case report lit-
erature and should be in the mind of the clinician faced
with a serious infection in a patient with an unknown
pathogen who is being treated with etanercept, inflixi-
mab, or adalimumab [5]. Staphylococcus aureus repre-
sented the most frequent causative pathogen and was
mostly associated with bones and/or joints infections
and with a worse outcome compared to that observed
with other bacterial pathogens. Bacterial infections seem
to occur early, within the first 6 months after the initi-
ation of TNF-α inhibitor therapies [12, 13]. There is no
evidence for an increased rate of staphylococcal carriage
among anti- TNF-α treated patients [14].
TNF-α inhibitors are applied in underlying diseases
such as rheumatoid arthritis, psoriasis, Crohn’s disease,
and polyarteritis nodosa. The 38 % of patients had re-
ceived etanercept, 34 % were received with infliximab,
whereas the repartition of patients treated with TNF-α
inhibitors was 51 % for etanercept, 31 % for infliximab
in the whole study population [1]. The most frequent
pathogen was Staphylococcus aureus. The pathogen was,
in our case, Staphylococcus aureus, which showed the
frequent infection secondary to receiving TNF-α inhibi-
tors. The most common sites of secondary infection
were bones and joints. Other secondary sites of infec-
tions were urinary tract, lungs, digestive tract, dental
roots, muscles, and the central nervous system [1]. The
cardiac involvement found in our case is very rare.
Conclusions
This case shows the risk of severe bacterial endocarditis
from the initiation of TNF-α inhibitor therapy even in a
Fig. 3 Autopsy revealed the fresh thrombosis in left middle cerebral
artery
Fig. 4 Arrows show multiple mitral valve vegetations
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small dose, probably due to drug-induced immunological
insufficiency. Physicians should be aware of secondary in-
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